U.S. Markets open in 3 hrs 15 mins

Vistin Pharma ASA Navne-Aksjer (VP4.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
2.3450-0.0050 (-0.21%)
As of 10:30AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3500
Open2.3250
Bid2.3500 x 0
Ask2.3900 x 0
Day's Range2.3250 - 2.3500
52 Week Range1.0250 - 2.7400
Volume0
Avg. Volume40
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Don't Buy F.N.B. Corporation (NYSE:FNB) For Its Next Dividend Without Doing These Checks
    Simply Wall St.

    Don't Buy F.N.B. Corporation (NYSE:FNB) For Its Next Dividend Without Doing These Checks

    Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

  • Vistin Pharma ASA: Meldepliktig handel
    GlobeNewswire

    Vistin Pharma ASA: Meldepliktig handel

    Intertrade Shipping AS har i dag kjøpt 148 461 aksjer i Vistin Pharma ASA til gjennomsnittskurs 16,25 per aksje. Intertrade Shipping AS eier etter kjøpet 11 075 000 aksjer i Vistin Pharma, tilsvarende 24.9% av selskapets utestående aksjer. Intertrade Shipping AS er kontrollert av Øyvin Brøymer som er Styreformann i Vistin Pharma ASA.

  • Vistin Pharma ASA: Third quarter and YTD 2020 financial results
    GlobeNewswire

    Vistin Pharma ASA: Third quarter and YTD 2020 financial results

    Oslo, Norway, 30 October 2020 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter and YTD 2020.The revenues for the third quarter of 2020 ended at MNOK 55 (Q3’19: MNOK 68). YTD 2020 the revenue was MNOK 189, compared to MNOK 171 in the first three quarters of 2019, a growth of 11%.Third quarter EBITDA for pharmaceuticals was MNOK 9.5 (Q3’19: MNOK 11.8), and YTD 2020 EBITDA of MNOK 44.3, compared to MNOK 23.6 in the first three quarters of 2019, an 88% increase.The net profit for the group ended at MNOK 4.5 (Q3’19: MNOK 59.6) for the third quarter of 2020. For first three quarters of 2020 the net loss was MNOK 105.6, compared to a profit of MNOK 59.6 YTD 2019. The net loss in 2020 is driven by the closing of the oil derivative portfolio in March.Vistin Pharma had cash of MNOK 97.5 (Q3’19 MNOK: 305) as of 30 September 2020. First installment of 15% for the Metformin Expansion Project (MEP) was paid in September. The company has a strong balance sheet with an equity ratio of 83% and no interest-bearing debt.  The third quarter conference call, which will be held today, 30 October, at 8.30am (CET) and will be available via web and audio through the following access points:Telephone conference: Confirmation Code:........ 9184755 International Dial-In:........ +44 (0) 2071 928338 Norway, Oslo:................ +47 21563015 United States, New York: +1 6467413167Webcast: https://edge.media-server.com/mmc/p/r4qc96ixThe conference call will be held in Norwegian.        Please find the Q3 report and presentation enclosed. The report will also be made available on www.vistin.com.*****For further information, please contact:Kjell-Erik Nordby CEO +47 91 36 42 80 kjell-erik.nordby@vistin.comAlexander Karlsen CFO +47 97 05 36 21 alexander.karlsen@vistin.comThis information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.  Attachments * Vistin Pharma ASA third quarter presentation 2020 * Vistin Pharma ASA third quarter report 2020